{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:46:28Z","timestamp":1784227588188,"version":"3.55.0"},"reference-count":89,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/inf.0b013e31828b7def","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T12:04:31Z","timestamp":1360670671000},"page":"e305-e313","source":"Crossref","is-referenced-by-count":67,"title":["Primary Versus Secondary Failure After Varicella Vaccination"],"prefix":"10.1097","volume":"32","author":[{"given":"Paolo","family":"Bonanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kulcs\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Papaevangelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Rentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sadzot-Delvaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vytautas","family":"Usonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Vesikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Weil-Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210202","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa042271","article-title":"Decline in mortality due to varicella after implementation of varicella vaccination in the United States.","volume":"352","author":"Nguyen","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-21-20210202","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995-2000.","volume":"287","author":"Seward","year":"2002","journal-title":"JAMA"},{"key":"R3-21-20210202","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0b013e3181bbf2a0","article-title":"Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella.","volume":"29","author":"Shah","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R4-21-20210202","doi-asserted-by":"crossref","first-page":"19530","DOI":"10.2807\/ese.15.13.19530-en","article-title":"Impact of the routine varicella vaccination programme on varicella epidemiology in Germany.","volume":"15","author":"Siedler","year":"2010","journal-title":"Euro Surveill"},{"key":"R5-21-20210202","doi-asserted-by":"crossref","first-page":"19321","DOI":"10.2807\/ese.14.35.19321-en","article-title":"Universal varicella vaccination in the Sicilian paediatric population: rapid uptake of the vaccination programme and morbidity trends over five years.","volume":"14","author":"Giammanco","year":"2009","journal-title":"Euro Surveill"},{"key":"R6-21-20210202","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/INF.0b013e3181e2817f","article-title":"Complications of varicella after implementation of routine childhood varicella vaccination in Germany.","volume":"29","author":"Spackova","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R7-21-20210202","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/adc.2007.126243","article-title":"Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005.","volume":"93","author":"Quian","year":"2008","journal-title":"Arch Dis Child"},{"key":"R8-21-20210202","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.1016\/j.vaccine.2011.10.022","article-title":"Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy.","volume":"29","author":"Pozza","year":"2011","journal-title":"Vaccine"},{"issue":"suppl 2","key":"R9-21-20210202","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/522145","article-title":"Varicella vaccine effectiveness in the US vaccination program: a review.","volume":"197","author":"Seward","year":"2008","journal-title":"J Infect Dis"},{"key":"R10-21-20210202","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMoa064040","article-title":"Loss of vaccine-induced immunity to varicella over time.","volume":"356","author":"Chaves","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"R11-21-20210202","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1086\/522151","article-title":"Perspective on live varicella vaccine.","volume":"197","author":"Gershon","year":"2008","journal-title":"J Infect Dis"},{"key":"R12-21-20210202","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/infdis\/jiq052","article-title":"Effectiveness of 2 doses of varicella vaccine in children.","volume":"203","author":"Shapiro","year":"2011","journal-title":"J Infect Dis"},{"key":"R13-21-20210202","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/01.inf.0000232631.06763.8b","article-title":"Varicella vaccine effectiveness during an outbreak in a partially vaccinated population in Spain.","volume":"25","author":"Arnedo-Pena","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R14-21-20210202","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2007.07.010","article-title":"Metaanalysis of vaccine effectiveness in varicella outbreaks.","volume":"25","author":"Bayer","year":"2007","journal-title":"Vaccine"},{"key":"R18-21-20210202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/340868","article-title":"An Outbreak of Varicella among children attending preschool and elementary school in Illinois.","volume":"35","author":"Dworkin","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R19-21-20210202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/341089","article-title":"Younger age at vaccination may increase risk of varicella vaccine failure.","volume":"186","author":"Galil","year":"2002","journal-title":"J Infect Dis"},{"key":"R20-21-20210202","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa021662","article-title":"Outbreak of varicella at a day-care center despite vaccination.","volume":"347","author":"Galil","year":"2002","journal-title":"N Engl J Med"},{"key":"R21-21-20210202","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/INF.0b013e31819c1041","article-title":"An outbreak of varicella in elementary school children with two-dose varicella vaccine recipients-Arkansas, 2006.","volume":"28","author":"Gould","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R22-21-20210202","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1542\/peds.2004-1826","article-title":"Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003.","volume":"115","author":"Haddad","year":"2005","journal-title":"Pediatrics"},{"key":"R23-21-20210202","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/jama.1997.03550180045035","article-title":"Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center.","volume":"278","author":"Izurieta","year":"1997","journal-title":"JAMA"},{"key":"R24-21-20210202","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1471-2458-11-226","article-title":"An outbreak of varicella among schoolchildren in Taipei.","volume":"11","author":"Lai","year":"2011","journal-title":"BMC Public Health"},{"key":"R25-21-20210202","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/422041","article-title":"An elementary school outbreak of varicella attributed to vaccine failure: policy implications.","volume":"190","author":"Lee","year":"2004","journal-title":"J Infect Dis"},{"key":"R27-21-20210202","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1542\/peds.2004-1162","article-title":"Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003.","volume":"115","author":"Marin","year":"2005","journal-title":"Pediatrics"},{"key":"R28-21-20210202","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.inf.0000154323.20387.82","article-title":"Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage.","volume":"24","author":"Miron","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 2","key":"R29-21-20210202","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1086\/522134","article-title":"Challenges to implementing second-dose varicella vaccination during an outbreak in the absence of a routine 2-dose vaccination requirement-Maine, 2006.","volume":"197","author":"Parker","year":"2008","journal-title":"J Infect Dis"},{"key":"R30-21-20210202","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2009.10.086","article-title":"Comparative varicella vaccine effectiveness during outbreaks in day-care centres.","volume":"28","author":"Spackova","year":"2010","journal-title":"Vaccine"},{"key":"R31-21-20210202","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.vaccine.2009.11.047","article-title":"Report of varicella outbreak in a low vaccination coverage group of otherwise healthy children in Italy: the role of breakthrough and the need of a second dose of vaccine.","volume":"28","author":"Tafuri","year":"2010","journal-title":"Vaccine"},{"key":"R34-21-20210202","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.291.7.851","article-title":"Effectiveness over time of varicella vaccine.","volume":"291","author":"Vazquez","year":"2004","journal-title":"JAMA"},{"key":"R35-21-20210202","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1056\/NEJM200103293441302","article-title":"The effectiveness of the varicella vaccine in clinical practice.","volume":"344","author":"Vazquez","year":"2001","journal-title":"N Engl J Med"},{"key":"R36-21-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.inf.0000114906.78716.64","article-title":"Use of a computerized database to study the effectiveness of an attenuated varicella vaccine.","volume":"23","author":"Passwell","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R37-21-20210202","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.inf.0000160947.89942.30","article-title":"Effectiveness of the OkaGSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel.","volume":"24","author":"Sheffer","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R38-21-20210202","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.vaccine.2011.01.092","article-title":"Varicella breakthrough infection and vaccine effectiveness in Taiwan.","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"R39-21-20210202","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00365549709035882","article-title":"Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination.","volume":"29","author":"Hirose","year":"1997","journal-title":"Scand J Infect Dis"},{"issue":"suppl 3","key":"R40-21-20210202","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1093\/infdis\/174.Supplement_3.S330","article-title":"Efficacy of high-titer live attenuated varicella vaccine in healthy young children.","volume":"174","author":"Varis","year":"1996","journal-title":"J Infect Dis"},{"issue":"suppl 2","key":"R41-21-20210202","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1086\/522124","article-title":"Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program.","volume":"197","author":"Black","year":"2008","journal-title":"J Infect Dis"},{"key":"R42-21-20210202","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1542\/peds.112.2.e98","article-title":"Vaccine Safety Datalink Research Group. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination.","volume":"112","author":"Verstraeten","year":"2003","journal-title":"Pediatrics"},{"key":"R43-21-20210202","doi-asserted-by":"crossref","first-page":"e1548","DOI":"10.1542\/peds.2007-2031","article-title":"Vaccine-era varicella epidemiology and vaccine effectiveness in a public elementary school population, 2002-2007.","volume":"121","author":"Lee","year":"2008","journal-title":"Pediatrics"},{"key":"R44-21-20210202","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1016\/j.ijid.2011.03.016","article-title":"Varicella rates among unvaccinated and one-dose vaccinated healthy children in Izmir, Turkey.","volume":"15","author":"Kurugol","year":"2011","journal-title":"Int J Infect Dis"},{"key":"R45-21-20210202","first-page":"259","article-title":"Reactogenicity and immunogenicity of a varicella vaccine in healthy seronegative and seropositive subjects.","volume":"33","author":"Barzaga","year":"2002","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"R46-21-20210202","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/00006454-199510000-00011","article-title":"Over five-year follow-up of OkaMerck varicella vaccine recipients in 465 infants and adolescents.","volume":"14","author":"Clements","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"R47-21-20210202","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4269\/ajtmh.2004.70.273","article-title":"Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old.","volume":"70","author":"Gatchalian","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"R48-21-20210202","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1741-7015-7-16","article-title":"Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.","volume":"7","author":"Gillet","year":"2009","journal-title":"BMC Med"},{"key":"R49-21-20210202","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.vaccine.2008.10.064","article-title":"Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.","volume":"27","author":"Gillet","year":"2009","journal-title":"Vaccine"},{"key":"R50-21-20210202","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1542\/peds.100.5.761","article-title":"A long-term prospective study of varicella vaccine in healthy children.","volume":"100","author":"Johnson","year":"1997","journal-title":"Pediatrics"},{"key":"R51-21-20210202","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1442-200x.2000.01300.x","article-title":"Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children.","volume":"42","author":"Kanra","year":"2000","journal-title":"Pediatr Int"},{"key":"R52-21-20210202","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jinf.2010.04.001","article-title":"Seroprevalence rate after one dose of varicella vaccine in infants.","volume":"61","author":"Kim","year":"2010","journal-title":"J Infect"},{"key":"R53-21-20210202","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00006454-200204000-00014","article-title":"Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.","volume":"21","author":"Li","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R54-21-20210202","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/adc.79.6.478","article-title":"Risk factors for breakthrough varicella in healthy children.","volume":"79","author":"Lim","year":"1998","journal-title":"Arch Dis Child"},{"issue":"suppl 3","key":"R56-21-20210202","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1093\/infdis\/174.Supplement_3.S324","article-title":"Immunogenicity and safety of a live attenuated varicella vaccine (OkaSB Bio) in healthy children.","volume":"174","author":"Meurice","year":"1996","journal-title":"J Infect Dis"},{"key":"R57-21-20210202","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/529043","article-title":"Primary vaccine failure after 1 dose of varicella vaccine in healthy children.","volume":"197","author":"Michalik","year":"2008","journal-title":"J Infect Dis"},{"key":"R58-21-20210202","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00006454-199601000-00011","article-title":"Safety and immunogenicity of one vs. two injections of OkaMerck varicella vaccine in healthy children.","volume":"15","author":"Ngai","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"R59-21-20210202","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1542\/peds.2007-1064","article-title":"LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.","volume":"121","author":"Nolan","year":"2008","journal-title":"Pediatrics"},{"key":"R60-21-20210202","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0264-410X(02)00459-0","article-title":"Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.","volume":"21","author":"Nolan","year":"2002","journal-title":"Vaccine"},{"key":"R61-21-20210202","first-page":"1295","article-title":"Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months.","volume":"85","author":"Ramkissoon","year":"1995","journal-title":"S Afr Med J"},{"key":"R62-21-20210202","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1016\/j.vaccine.2011.02.067","article-title":"Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses.","volume":"29","author":"Rumke","year":"2011","journal-title":"Vaccine"},{"key":"R63-21-20210202","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/INF.0b013e318170bb22","article-title":"Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.","volume":"27","author":"Schuster","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R64-21-20210202","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.inf.0000172902.25009.a1","article-title":"Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.","volume":"24","author":"Shinefield","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R65-21-20210202","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/01.inf.0000172901.29621.e9","article-title":"Dose Selection Study Group for Proquad. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.","volume":"24","author":"Shinefield","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R66-21-20210202","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00006454-200206000-00014","article-title":"Kaiser Permanente Medical Team for Varivax. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children.","volume":"21","author":"Shinefield","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R67-21-20210202","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/INF.0b013e318060d33d","article-title":"Immunogenicity of OkaMerck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.","volume":"26","author":"Silber","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R68-21-20210202","first-page":"113","article-title":"Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age.","volume":"20","author":"Stuck","year":"2002","journal-title":"Asian Pac J Allergy Immunol"},{"key":"R69-21-20210202","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/BF01957158","article-title":"Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham BiologicalsOka) in healthy children.","volume":"155","author":"Tan","year":"1996","journal-title":"Eur J Pediatr"},{"key":"R70-21-20210202","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1067\/mpd.2001.116051","article-title":"Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy.","volume":"139","author":"Vessey","year":"2001","journal-title":"J Pediatr"},{"key":"R71-21-20210202","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/infdis\/172.1.217","article-title":"Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization.","volume":"172","author":"Watson","year":"1995","journal-title":"J Infect Dis"},{"key":"R72-21-20210202","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/infdis\/173.3.731","article-title":"Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.","volume":"173","author":"Watson","year":"1996","journal-title":"J Infect Dis"},{"key":"R73-21-20210202","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/338959","article-title":"Persistence of immunity to live attenuated varicella vaccine in healthy adults.","volume":"34","author":"Ampofo","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R74-21-20210202","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/501900","article-title":"Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers.","volume":"22","author":"Saiman","year":"2001","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R76-21-20210202","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/clinids\/20.2.316","article-title":"Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine.","volume":"20","author":"Watson","year":"1995","journal-title":"Clin Infect Dis"},{"key":"R77-21-20210202","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s15010-006-5616-9","article-title":"Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.","volume":"34","author":"Ludwig","year":"2006","journal-title":"Infection"},{"key":"R79-21-20210202","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/INF.0b013e3181d7380e","article-title":"The effectiveness of varicella vaccine in China.","volume":"29","author":"Fu","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R80-21-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1067\/mic.2003.58","article-title":"Varicella vaccine safety, incidence of breakthrough, and factors associated with breakthrough in Taiwan.","volume":"31","author":"Tseng","year":"2003","journal-title":"Am J Infect Control"},{"key":"R81-21-20210202","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/S0264-410X(00)00016-5","article-title":"Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic.","volume":"18","author":"Ozaki","year":"2000","journal-title":"Vaccine"},{"key":"R82-21-20210202","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1442-200X.1997.tb03664.x","article-title":"High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain).","volume":"39","author":"Takayama","year":"1997","journal-title":"Acta Paediatr Jpn"},{"key":"R83-21-20210202","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0264-410X(00)00100-6","article-title":"Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes.","volume":"18","author":"Brisson","year":"2000","journal-title":"Vaccine"},{"key":"R84-21-20210202","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006454-199201000-00006","article-title":"Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.","volume":"11","author":"White","year":"1992","journal-title":"Pediatr Infect Dis J"},{"key":"R85-21-20210202","first-page":"697","article-title":"Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults.","volume":"35","author":"Kosuwon","year":"2004","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"R86-21-20210202","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1016\/j.vaccine.2009.07.076","article-title":"A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.","volume":"27","author":"Czajka","year":"2009","journal-title":"Vaccine"},{"key":"R87-21-20210202","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s15010-007-6337-z","article-title":"Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.","volume":"35","author":"Goh","year":"2007","journal-title":"Infection"},{"key":"R88-21-20210202","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.vaccine.2009.02.044","article-title":"Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.","volume":"27","author":"Halperin","year":"2009","journal-title":"Vaccine"},{"key":"R89-21-20210202","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.inf.0000195626.35239.58","article-title":"Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.","volume":"25","author":"Knuf","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R90-21-20210202","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Study Group for Varivax. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R91-21-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1542\/peds.2005-0092","article-title":"Protocol 014 Study Group for ProQuad. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.","volume":"117","author":"Reisinger","year":"2006","journal-title":"Pediatrics"},{"key":"R92-21-20210202","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.inf.0000250689.09396.21","article-title":"Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.","volume":"26","author":"Vesikari","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R94-21-20210202","first-page":"567","article-title":"Varicella: efficacy of two-dose vaccination in childhood.","volume":"105","author":"Wutzler","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"R95-21-20210202","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0264-410X(95)00046-4","article-title":"Safety, tolerability, and immunogenicity of two regimens of OkaMerck varicella vaccine (Varivax) in healthy adolescents and adults. OkaMerck Varicella Vaccine Study Group.","volume":"13","author":"Kuter","year":"1995","journal-title":"Vaccine"},{"key":"R96-21-20210202","doi-asserted-by":"crossref","first-page":"19548","DOI":"10.2807\/ese.15.16.19548-en","article-title":"Changes to the varicella and pertussis immunisation schedule in Germany 2009: background, rationale and implementation.","volume":"15","author":"Wiese-Posselt","year":"2010","journal-title":"Euro Surveill"},{"issue":"RR-3","key":"R97-21-20210202","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Marin","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"RR-4","key":"R98-21-20210202","first-page":"1","article-title":"Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"R99-21-20210202","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/INF.0b013e3181d9f657","article-title":"Incremental effectiveness of second dose varicella vaccination for outbreak control at an elementary school in Philadelphia, pennsylvania, 2006.","volume":"29","author":"Nguyen","year":"2010","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e31828b7def","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T13:36:39Z","timestamp":1644327399000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201307000-00021"}},"subtitle":["Implications for Interval Between 2 Doses"],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31828b7def","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}